Nutrix, a Swiss medical technology startup, was awarded the EVIG Alfa equity fund, which financially supports innovative projects at an early stage of development, and which is financed by private investors and capital from National Center for Research and Development.
EVIG Alfa’s investment will be used by Nutrix to develop software and AI algorithms that help monitor the glucose present in saliva in the treatment of diabetes. The overriding goal of the start-up is to use the full potential of artificial intelligence to give people the ability to monitor their health in an easy, non-invasive and painless way.
“ We are very pleased with this demonstration of trust as it brings us closer to our goal of ensuring the well-being of patients with chronic diseases such as diabetes, which affects 10% to 12% of the population in European countries,” said Maria Hahn, CEO of Nutrix.